Pd 1 Pd L1 Inhibitors Competitive Landscape Pipeline Market Analysis

DelveInsight’s, “PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope

• The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for PD and PD-L1 inhibitors

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling

• The report also gives the information of dormant pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

• Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Introduction

Executive Summary

Programmed Death 1 (PD-1)

Programmed Death Ligand 1 (PD-L1)

Role of PD-1 and PD-L1 pathways

MOA of PD-1 and PD-L1 inhibitors

Significance of PD-1 and PD-L1 inhibitors

PD-1 and PD-L1 Active Therapy Areas & Epidemiology

Metastatic Renal Cell Carcinoma

Squamous Cell Carcinomas of the Head and Neck

Metastatic Colorectal Cancer

Non-Small Cell lung cancer

Biomarkers - PD-1 and PD-L1 inhibitors

Market Overview

Comparative Analysis of Pipeline &Marketed Drugs

Marketed Product of PD-1 and PD-L1 drugs –Overview

Marketed Drug Candidate Profiles

Pembrolizumab

Nivolumab

Atezolizumab

Marketed Drugs Sales

Details of Patent Expiry of Marketed Drugs

Current and Future Market for PD and PD-L1 inhibitors

Challenges and Barriers associated with use of PD and PD-L1 inhibitors

PD-1/PD-L1Combinations Creating Boom

Pipeline Therapeutics

An overview of pipeline products

Pipeline Therapeutics Overview

Therapeutics under Development by MOA

Therapeutics under Development by Companies

Last Stage Products (Phase III and Filed)

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I and IND)

Comparative Analysis

Pre-Clinical and Discovery Products

Comparative Analysis

Unknown Stages Molecules

Therapeutic Assessment of pipeline

Therapeutics under Development by Product Type

Therapeutics under Development by Phase for Monotherapy

Therapeutics under Development by Phase for Combination therapy

Therapeutics under Development by Molecule Type

Assessment by Stage and Molecule Type

Therapeutics under Development by Route of Administration

Assessment by Stage and Route of Administration

Dormant Products

Comparative Analysis

SWOT Analysis

Appendix

Methodology

Consulting Services

About DelveInsight

Contact Us

Disclaimer

Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017

Table 2: PD-1 Marketed Drugs, 2017

Table 3: Sales of Marketed drugs, 2017

Table 4: Details of patent expiry of marketed molecules, 2017

Table 5: Merck’s drug- Keytruda (Pembrolizumab) Partners for Combination Therapies

Table 6:Bristol Myers Squibb’s drug-Opdivo (nivolumab) Partners for Combination Therapies

Table 7: Roche’s drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies

Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017

Table 9: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2017

Table 10: Number of Products under Development by Companies, 2017

Table 11: Last Stage Products (Phase III and Filed),2017

Table 12: Mid Stage Products (Phase II), 2017

Table 13: Early Stage Products (Phase I and IND), 2017

Table 14: Pre-Clinical and Discovery Products, 2017

Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017

Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017

Table 17:Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017

Table 18: Number of Products under Development by Molecule Type, 2017

Table 19: Assessment by Stage and Molecule Type, 2017

Table 20:Number of Products under Development by Route of Administration, 2017

Table 21:Assessment by Stage and Route Of Administration, 2017

Table 22: Dormant Products, 2017

Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017

Figure 2: Sales of marketed drugs, 2017

Figure 3: Details of patent expiry of marketed molecules, 2017

Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2017

Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2017

Figure 6:Last Stage Products (Phase III), 2017

Figure 7: Mid Stage Products (Phase II), 2017

Figure 8: Early Stage Products (Phase I and IND), 2017

Figure 9:Pre-Clinical and Discovery Products, 2017

Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2017

Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2017

Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017

Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017

Figure 14: Assessment by Stage and Molecule Type, 2017

Figure 15:Percentage of pipeline drugs by Route of Administration(%), 2017

Figure 16: Assessment by Stage and Route of Administration, 2017

Figure 17: Dormant Products, 2017

Agenus Inc

Alnylam

AstraZeneca plc

Aurigene

BeiGene

Bristol Myers Squibb

Cellular Biomedicines Group

Curis, Inc.

CytomX Therapeutics

EMD Serono, Inc

Enumeral

GlaxoSmithKline

Hoffmann-La Roche

Immunovo

Incyte Corporation

Indus Biotech

Indus Biotech Private Limited

Kadmon Corporation, LLC

Kymab Ltd

MacroGenics

MedImmune LLC

Merck Sharp & Dohme Corp.

Merus B.V.

North Coast Bio LLC

Novartis

Novartis

Ono Pharmaceutical Co., Ltd

PharmaEssentia

PxRadia, Inc.

Regeneron Pharmaceuticals Inc

Sorrento Therapeutics

Sutro Biopharma, Inc.

Tesaro

TG Therapeutics

Theravectys

Tikcro

Transgene 

  • Tags:
  • "• PD-1 and PD-L1 Inhibitors Therap...

Forward to Friend

Need A Quote